Bonnie Hammer
EVP of R&D Invenra
Seminars
Tuesday 4th November 2025
Showcasing Invenra’s Bispecific B-Body® & Trispecific T-Body™ Platforms: Versatile Multispecific Systems for Broad-Spectrum ADC Discovery
11:30 am
- Building Invenra’s proprietary B-Body and T-Body multispecific platforms for rapid, in-format discovery as well as for simple manufacturing
- Combining two multispecific platforms to provide a rapid screening system to empirically identify optimal bispecific and trispecific ADC target combinations
- Describing generation of a 12×12 matrix of bispecific B-Body antibodies targeting 6 antigens to identify optimal pairs for trispecific T-Body ADCs for breast cancer
- Highlighting two powerful platforms for next-generation ADCs, offering promise for more effective and versatile breast cancer therapies
